Search Within

Michael Andrew Postow

Formats
  1. Journal Article (196)
  2. Meeting Abstract (138)
  3. Review (10)
  4. Editorial (9)
  5. Book Section (4)
  6. Guidelines (4)
  7. Research Letter (4)
  8. Miscellaneous (2)
  9. Book Whole (1)
  10. Correspondence (1)
Groups
  1. Department of Medicine (369)
  2. Melanoma Disease Management Team (369)
  3. Melanoma and Immunotherapeutics Service (369)
  4. Solid Tumor Oncology Division (369)
  5. GSK Faculty (178)
  6. Hematologic Malignancies, Division of (105)

More Groups

People
  1. Jedd Wolchok (158)
  2. Margaret Callahan (96)
  3. Katherine Panageas (66)
  4. Alexander Shoushtari (64)
  5. Paul Chapman (55)
  6. Parisa Momtaz (37)

More People

Years
  1. 2025 (23)
  2. 2024 (19)
  3. 2023 (23)
  4. 2022 (23)
  5. 2021 (27)
  6. 2020 (30)

More Years

Publications
  1. Journal of Clinical Oncology (92)
  2. Journal for ImmunoTherapy of Cancer (34)
  3. Clinical Cancer Research (16)
  4. Annals of Oncology (13)
  5. International Journal of Radiation Oncology, Biology, Physics (12)
  6. The Oncologist (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (94)
  2. Biomed Central Ltd (43)
  3. Elsevier Inc. (32)
  4. Oxford University Press (32)
  5. American Association for Cancer Research (24)
  6. Wiley Blackwell (21)

More Publishers

Results (369)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
    Journal Article

    Valero, C.; Lee, M.; Hoen, D.; Weiss, K.; Kelly, D. W.; Adusumilli, P. S.; Paik, P. K.; Plitas, G.; Ladanyi, M.; Postow, M. A.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
    Journal Article

    Beattie, J.; Rizvi, H.; Fuentes, P.; Luo, J.; Schoenfeld, A.; Lin, I. H.; Postow, M.; Callahan, M.; Voss, M. H.; Shah, N. J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • The association between tumor mutational burden and prognosis is dependent on treatment context
    Research Letter

    Valero, C.; Lee, M.; Hoen, D.; Wang, J.; Nadeem, Z.; Patel, N.; Postow, M. A.; Shoushtari, A. N.; Plitas, G.; Balachandran, V. P.; more...
    Nature Genetics (2021)

    Fulltext@MSK | Save
  • Combinatorial approaches to the treatment of advanced melanoma
    Review

    Munhoz, R. R.; Postow, M. A.
    Hematology/Oncology Clinics of North America (2021)

    Fulltext@MSK | Save
  • Checkpoint blockade in melanoma patients with underlying chronic lymphocytic leukemia
    Journal Article

    Smithy, J. W.; Pianko, M. J.; Maher, C.; Postow, M. A.; Shoushtari, A. N.; Momtaz, P.; Chapman, P. B.; Wolchok, J. D.; Park, J. H.; Callahan, M. K.
    Journal of Immunotherapy (2021)

    Fulltext@MSK | Save
  • Melanoma brain metastasis: Presentation, treatment and outcomes in the age of targeted- and immuno-therapies
    Meeting Abstract

    Bander, E. D.; Yuan, M.; Carnevale, J. A.; Reiner, A. S.; Panageas, K. S.; Postow, M. A.; Tabar, V.; Moss, N. S.
    Neuro-Oncology Advances (2020)

    Fulltext@MSK | Save
  • Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors
    Meeting Abstract

    Mita, M.; Mita, A.; Hamilton, E.; Falchook, G. S.; Postow, M.; Chmielowski, B.; Schilder, R. J.; Strauss, J.; Lim, E.; Pant, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Updated clinical data from the melanoma expansion cohort of an ongoing ph1/1b study of eganelisib (formerly IPI-549) in combination with nivolumab
    Meeting Abstract

    Postow, M.; Sullivan, R.; Cohen, E.; Gutierrez, M.; Hong, D.; Steuer, C.; McCarter, J.; Zizlsperger, N.; Kutok, J.; O'Connell, B.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma
    Meeting Abstract

    Dummer, R.; Long, G. V.; Pavlick, A.; Postow, M.; Ribas, A.; Robert, C.; Scolyer, R. A.; Taube, J.; Tetzlaff, M.; Liao, J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b study of eganelisib (formerly IPI-549) in combination with nivolumab
    Meeting Abstract

    Cohen, E.; Postow, M.; Sullivan, R.; Hong, D.; Yeckes-Rodin, H.; McCarter, J.; Zizlsperger, N.; Kutok, J.; O'Connell, B.; Page, K.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save